More than a decade after coining “Treat Yo’ Self Day” in her role as Donna on “Parks & Recreation,” Retta is once again ...

Both of Abbott's over-the-counter CGMS are based on its popular FreeStyle Libre sensor technology, as Dexcom's prescription-free Stelo follows the popular G6 and G7 CGM technology for people who ...

The announcement comes just after Dexcom, another diabetes company, released its own consumer-friendly sensor. Here's what to know about glucose monitoring. Jessica is a writer on the Wellness ...

Wells Fargo analyst Larry Biegelsen maintained a Buy rating on Dexcom (DXCM – Research Report) yesterday and set a price target of ...

Dexcom has pitched the Stelo as a more “health-focused” version of its top-of-the-line CGM, the G7, which made its debut early last year. Though built on the same sensor platform, the Stelo ...

New over-the-counter sensors, an Abbott-Medtronic partnership and Roche’s first CGM are among diabetes technology’s top stories so far in 2024. Check out MedTech Dive’s roundup of the latest news.

Results obtained from previous Dexcom device(s) in people with diabetes who may be on insulin. ‡A study was conducted to assess the sensor life where 77.9% of sensors lasted the full 15 days.

Patients could buy a pack of two sensors at a one-time price of $99 or opt for a subscription to get a monthly delivery for $89, Dexcom said. Abbott had said it plans to launch Lingo in the U.S ...

DexCom is one of the leaders in an industry with massive growth potential. The company is building a competitive advantage. Despite several risks, it could deliver substantial returns in the long ...

I managed to lose seven pounds. SAN DIEGO, September 18, 2024--DexCom, Inc. (NASDAQ: DXCM), the global leader in real-time continuous glucose monitoring (CGM) for people with diabetes, announced ...